These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 27896545)

  • 21. Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study.
    Sheppard M; Bronstein MD; Freda P; Serri O; De Marinis L; Naves L; Rozhinskaya L; Hermosillo Reséndiz K; Ruffin M; Chen Y; Colao A
    Pituitary; 2015 Jun; 18(3):385-94. PubMed ID: 25103549
    [TBL] [Abstract][Full Text] [Related]  

  • 22. De-escalation treatment with pasireotide for acromegaly: a long-term experience.
    Giampietro A; Menotti S; Chiloiro S; Pontecorvi A; De Marinis L; Bianchi A
    Endocrine; 2023 Jun; 80(3):505-510. PubMed ID: 36808072
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pasireotide for acromegaly: long-term outcomes from an extension to the Phase III PAOLA study.
    Colao A; Bronstein MD; Brue T; De Marinis L; Fleseriu M; Guitelman M; Raverot G; Shimon I; Fleck J; Gupta P; Pedroncelli AM; Gadelha MR
    Eur J Endocrinol; 2020 Jun; 182(6):583. PubMed ID: 32217809
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of the Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Inadequately Controlled With First-Generation Somatostatin Analogs.
    Gadelha M; Bex M; Colao A; Pedroza García EM; Poiana C; Jimenez-Sanchez M; Yener S; Mukherjee R; Bartalotta A; Maamari R; Raverot G
    Front Endocrinol (Lausanne); 2019; 10():931. PubMed ID: 32117045
    [No Abstract]   [Full Text] [Related]  

  • 25. Long-term safety and efficacy of long-acting pasireotide in acromegaly.
    Akirov A; Gorshtein A; Dotan I; Khazen NS; Pauker Y; Gershinsky M; Shimon I
    Endocrine; 2021 Nov; 74(2):396-403. PubMed ID: 34081309
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serial follow-up of presurgical treatment using pasireotide long-acting release with or without octreotide long-acting release for naïve active acromegaly.
    Chang JS; Tseng HM; Chang TC
    J Formos Med Assoc; 2016 Jun; 115(6):475-80. PubMed ID: 27117887
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study.
    Bronstein MD; Fleseriu M; Neggers S; Colao A; Sheppard M; Gu F; Shen CC; Gadelha M; Farrall AJ; Hermosillo Reséndiz K; Ruffin M; Chen Y; Freda P;
    BMC Endocr Disord; 2016 Apr; 16():16. PubMed ID: 27039081
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacotherapy for acromegaly: future role for pasireotide?
    Ben-Shlomo A
    Endocrinol Metab Clin North Am; 2015 Mar; 44(1):35-41. PubMed ID: 25732640
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial.
    Petersenn S; Schopohl J; Barkan A; Mohideen P; Colao A; Abs R; Buchelt A; Ho YY; Hu K; Farrall AJ; Melmed S; Biller BM;
    J Clin Endocrinol Metab; 2010 Jun; 95(6):2781-9. PubMed ID: 20410233
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of a new slow-release, long-acting somatostatin analogue, lanreotide, in acromegaly.
    al-Maskari M; Gebbie J; Kendall-Taylor P
    Clin Endocrinol (Oxf); 1996 Oct; 45(4):415-21. PubMed ID: 8959079
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group.
    Giusti M; Gussoni G; Cuttica CM; Giordano G
    J Clin Endocrinol Metab; 1996 Jun; 81(6):2089-97. PubMed ID: 8964833
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Managing pasireotide-associated hyperglycemia: a randomized, open-label, Phase IV study.
    Samson SL; Gu F; Feldt-Rasmussen U; Zhang S; Yu Y; Witek P; Kalra P; Pedroncelli AM; Pultar P; Jabbour N; Paul M; Bolanowski M
    Pituitary; 2021 Dec; 24(6):887-903. PubMed ID: 34275099
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Controlled With Pegvisomant and First-Generation Somatostatin Analogues (PAPE Study).
    Muhammad A; van der Lely AJ; Delhanty PJD; Dallenga AHG; Haitsma IK; Janssen JAMJL; Neggers SJCMM
    J Clin Endocrinol Metab; 2018 Feb; 103(2):586-595. PubMed ID: 29155991
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pansomatostatin Agonist Pasireotide Long-Acting Release for Patients with Autosomal Dominant Polycystic Kidney or Liver Disease with Severe Liver Involvement: A Randomized Clinical Trial.
    Hogan MC; Chamberlin JA; Vaughan LE; Waits AL; Banks C; Leistikow K; Oftsie T; Madsen C; Edwards M; Glockner J; Kremers WK; Harris PC; LaRusso NF; Torres VE; Masyuk TV
    Clin J Am Soc Nephrol; 2020 Sep; 15(9):1267-1278. PubMed ID: 32843370
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and tolerability of the long-acting somatostatin analog lanreotide in acromegaly. A 12-month multicenter study of 58 acromegalic patients. French Multicenter Study Group on Lanreotide in Acromegaly.
    Chanson P; Leselbaum A; Blumberg J; Schaison G
    Pituitary; 2000 May; 2(4):269-76. PubMed ID: 11081148
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and Safety of switching to Pasireotide in Acromegaly Patients controlled with Pegvisomant and Somatostatin Analogues: PAPE extension study.
    Muhammad A; Coopmans EC; Delhanty PJD; Dallenga AHG; Haitsma IK; Janssen JAMJL; van der Lely AJ; Neggers SJCMM
    Eur J Endocrinol; 2018 Oct; 179(5):269-277. PubMed ID: 30076159
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of lanreotide autogel compared with lanreotide 40 mg prolonged release in Chinese patients with active acromegaly: results from a phase 3, prospective, randomized, and open-label study (LANTERN).
    An Z; Lei T; Duan L; Hu P; Gou Z; Zhang L; Durand-Gasselin L; Wang N; Wang Y; Gu F;
    BMC Endocr Disord; 2020 May; 20(1):57. PubMed ID: 32366244
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of anti-somatostatin agents on glucose metabolism.
    Vergès B
    Diabetes Metab; 2017 Oct; 43(5):411-415. PubMed ID: 28579289
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of the new 60-mg formulation of the long-acting somatostatin analog lanreotide in the treatment of acromegaly.
    Ambrosio MR; Franceschetti P; Bondanelli M; Doga M; Maffei P; Baldelli R; Tamburrano G; Sicolo N; Giustina A; degli Uberti EC
    Metabolism; 2002 Mar; 51(3):387-93. PubMed ID: 11887179
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety, tolerability, and pharmacokinetics of a single dose of pasireotide long-acting release in healthy volunteers: a single-center Phase I study.
    Dietrich H; Hu K; Ruffin M; Song D; Bouillaud E; Wang Y; Hasskarl J
    Eur J Endocrinol; 2012 May; 166(5):821-8. PubMed ID: 22383336
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.